Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › Orforglipron CVOT

Orforglipron CVOT

Orforglipron · Atherosclerotic CVD, obesity or T2D

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Orforglipron
Population
Atherosclerotic CVD, obesity or T2D
Official title
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Sponsor
Eli Lilly and Company
Phase
Phase 3
Registry status
recruiting · 2025-12 → 2031-08
Participants
7140
Registry
NCT07241390

Ongoing outcome trial

TrialMoleculePopulationPrimary endpointnRegistry statusPrimary completionRegistry
Orforglipron CVOTOrforglipronAtherosclerotic CVD, obesity or T2D
ASCVD and/or CKD with obesity or T2D
MACE7140recruiting2031-08NCT07241390

No results yet; the primary completion date comes from the registry.

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: Orforglipron CVOT. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/orforglipron-cvot/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.